The estimated Net Worth of Denelle J Waynick is at least $131 Thousand dollars as of 1 June 2021. Ms. Waynick owns over 584 units of MyoKardia stock worth over $131,347 and over the last 4 years she sold MYOK stock worth over $0. In addition, she makes $0 as General Counsel and Corporate Secretary at MyoKardia.
Denelle has made over 1 trades of the MyoKardia stock since 2021, according to the Form 4 filled with the SEC. Most recently she bought 584 units of MYOK stock worth $9,969 on 1 June 2021.
The largest trade she's ever made was buying 584 units of MyoKardia stock on 1 June 2021 worth over $9,969. On average, Denelle trades about 97 units every 0 days since 2020. As of 1 June 2021 she still owns at least 584 units of MyoKardia stock.
You can see the complete history of Ms. Waynick stock trades at the bottom of the page.
Denelle Waynick serves as General Counsel, Corporate Secretary of the Company. Ms. Waynick most recently served as Vice President, Legal Affairs (US), US General Counsel & Head of Global Enterprise Risk Management at UCB. In this role, Ms. Waynick served as the secretary and a member of the company's US Board of Directors overseeing its governance while also serving as a member of the US Leadership Team, which oversees corporate operations. During her tenure at UCB, she relocated to UCB's headquarters in Belgium for a year where she provided counsel to the global business units, including commercial operations, R&D, and the regulatory team. Prior to UCB, Ms. Waynick oversaw legal operations as Vice President, Legal Affairs, Global Brands at Actavis, Inc. (now AbbVie). In this role, she served as part of the global brand's executive team helping to lead the company's strategic growth plans through product in-licensing agreements and several acquisitions. She served as Legal Director at Schering-Plough (now Merck) where she provided legal support to the company's multi-million-dollar virology, respiratory and oncology product franchises on a myriad of legal and compliance issues. In addition to her roles as in-house counsel, Ms. Waynick was Chief of Staff for the Office of the New Jersey Attorney General. She began her legal career in the corporate law department of Paul Hastings in Los Angeles. Several years later, she joined the healthcare group at Gibbons P.C., in Newark, New Jersey, where she ultimately served as Partner.
Denelle Waynick is 53, she's been the General Counsel and Corporate Secretary of MyoKardia since 2020. There are 7 older and 4 younger executives at MyoKardia. The oldest executive at MyoKardia, Inc. is Mary Cranston, 72, who is the Independent Director.
Denelle's mailing address filed with the SEC is C/O ZOGENIX, INC., 5959 HORTON STREET, SUITE 500, EMERYVILLE, CA, 94608.
Over the last 9 years, insiders at MyoKardia have traded over $313,807,381 worth of MyoKardia stock and bought 2,317,816 units worth $42,556,877 . The most active insiders traders include Sanofi, Kevin P Starr, and Rock Ventures Ii, L.P.Third.... On average, MyoKardia executives and independent directors trade stock every 16 days with the average trade being worth of $21,462,936. The most recent stock trade was executed by Anastasios Gianakakos on 2 July 2020, trading 5,000 units of MYOK stock currently worth $469,900.
MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA.
MyoKardia executives and other stock owners filed with the SEC include: